Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Momenta Pharmaceuticals (MNTA) PT Raised to $15 at Stifel Following Positive M281 MAD Data, EYLEA Biosimilar Unveiling
January 5, 2018 12:40 PM ESTStifel analyst Alex Schwartz raised his price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $15.00 (from $12.00) while maintaining a Hold rating after the company announced positive topline data from the Phase 1 trial with M281.
Schwartz commented, "The anti-FcRn antibody demonstrated a favorable safety profile... More
Mylan (MYL) PT Raised to $44 at BofA/Merrill Lynch Following Generic Estrace Cream Approval
January 4, 2018 8:08 AM ESTBofA/Merrill Lynch raised its price target on Mylan (NASDAQ: MYL) to $44.00 (from $41.00) while maintaining a Neutral rating following the recent approval of generic Estrace Cream, Allergans womens health brand with $375m net sales. MYL recently launched (12/29) g-Estrace followed by an authorized... More
